GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiRx Inc (ROCO:6580) » Definitions » Loans Receivable

TaiRx (ROCO:6580) Loans Receivable : NT$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is TaiRx Loans Receivable?

TaiRx's Loans Receivable for the quarter that ended in Dec. 2023 was NT$0.00 Mil.


TaiRx Loans Receivable Historical Data

The historical data trend for TaiRx's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiRx Loans Receivable Chart

TaiRx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

TaiRx Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TaiRx Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


TaiRx Loans Receivable Related Terms

Thank you for viewing the detailed overview of TaiRx's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


TaiRx (ROCO:6580) Business Description

Traded in Other Exchanges
N/A
Address
No. 66, Sanchong Road, 1st Floor, 6th Floor, Nangang District, Taipei, TWN, 11502
TaiRx Inc is a pharmaceutical company based in Taiwan. It develops new drug and also makes improvements on current standard treatments in order to promptly find cures for major diseases and fulfill unmet medical needs. The company focuses on the new drug development for Asian and global markets.

TaiRx (ROCO:6580) Headlines

No Headlines